Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult to- sequence genomic regions that are missed with conventional sequencing techniques….
Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Using proven mass cytometry and microfluidic technologies, we provide workflows to identify and characterize changes in cellular phenotypes at the single-cell level. Whether you seek to target new biomarkers or to optimize the effectiveness of…